

**OPEN ACCESS JOURNAL AT INIST-CNRS** 

## Leukaemia Section

**Mini Review** 

## t(2;5)(p23;q35)

## Jean-Loup Huret

Genetics, Dept Medical Information, UMR 8125 CNRS, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France (JLH)

Published in Atlas Database: August 2001

Online updated version : http://AtlasGeneticsOncology.org/Anomalies/t0205.html DOI: 10.4267/2042/37790

This article is an update of: Huret JL. t(2;5)(p23;q35). Atlas Genet Cytogenet Oncol Haematol.1997;1(2):92-93.

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2001 Atlas of Genetics and Cytogenetics in Oncology and Haematology

## Identity



t(2;5)(p23;q35) G-banding (left), and R- banding (right); note tetraploid cells (left middle and bottom) - Courtesy Jean-Luc Lai and Alain Vanderhaegen.

## **Clinics and pathology**

## Disease

Translocations involving 2p23 are found in more than half cases of anaplasic large cell lymphoma (ALCL), a high grade non Hodgkin lymphoma (NHL). They involve ALK, and are therefore called ALK+ ALCL. The t(2;5) is the far most frequent 2p23 translocation in ALK+ ALCL.

## Phenotype/cell stem origin

T-cell in 80% (or 100%?), or null-cell type; B-cell cases, if they exist, would represent cases of large B-

cell lymphomas; CD30+; present with some overlapping features with Hodgkin's disease: CD30 positivity and Reed-Sternberg like cells, but the t(2;5) is not found in Hodgkin's disease (it has long been debated).

## Epidemiology

10% of NHL; found in children and young adults; median around 16 yrs).

#### Clinics

Involve lymph nodes and extra nodal sites such as lungs and gastro intestinal tract.

## Cytology

t(2;5) is found in about 30-50% of anaplastic large cell NHL (also called ALCL); it was thought previously that the t(2;5) could be found in diffuse large cell NHL or immunoblastic NHL; however, cases may easily be misdiagnosed, as the malignant cells display a pleomorphic appearance.

## Prognosis

Although t(2;5) is found in aggressive high grade tumours, a 80% five yr survival seems to be associated with this anomaly.

## Cytogenetics

## Additional anomalies

Sole anomaly in less than 20% of cases; often part of a complex karyotype, with various structural and/or numerical anomalies; recurrent numerical anomalies are: +7, found in 20% of cases, +9, and +X, in 5 to 10% of cases.

## Variants

Closely related anomalies, also found in anaplastic large cell lymphoma, are: t(X;2)(q11;p23), t(1;2)(q25;p23), inv(2)(p23q35), t(2;3)(p23;q21), t(2;17)(p23;q23), t(2;19)(p23; p13.1) and t(2;22)(p23;q11.2). They all involve ALK in 2p23.

## Genes involved and proteins

## ALK

Location

## 2p23

Protein

After glycosylation, produces a glycoprotein; membrane associated tyrosine kinase receptor.

## NPM1

Location 5q35

#### Protein

nuclear localisation; RNA binding nucleolar phosphoprotein involved in preribosomal assembly

# Result of the chromosomal anomaly

## Hybrid gene

Description 5' NPM-3' ALK on der(5). Transcript 2.4 kb

## Fusion protein

#### Description

80 kDa; 680 amino acids; the 116 N-term aminoacids from NPM are fused to the 563 C-term aminoacids of ALK (i.e. composed of the oligomerization domain and the metal binding site of NPM1, and the entire cytoplasmic portion of ALK); no apparent expression of the ALK/NPM1 counterpart. Characteristic localisation both in the cytoplasm and in the nucleus, due to heterooligomerization of NPM-ALK and normal NPM whereas the normal NPM protein is confined to the nucleus; constitutive activation of the catalytic domain of ALK.

#### **Expression / Localisation**

Localisation: both in the cytoplasm and in the nucleus (nucleoplasm and nucleolus).

#### Oncogenesis

Via the kinase function activated by oligomerization of NPM-ALK mediated by the NPM part.

## References

Mason DY, Bastard C, Rimokh R, Dastugue N, Huret JL, Kristoffersson U, Magaud JP, Nezelof C, Tilly H, Vannier JP. CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. Br J Haematol. 1990 Feb;74(2):161-8

Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994 Mar 4;263(5151):1281-4

Wellmann A, Otsuki T, Vogelbruch M, Clark HM, Jaffe ES, Raffeld M. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease. Blood. 1995 Sep 15;86(6):2321-8

Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphomaassociated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol. 1997 Apr;17(4):2312-25

Donner LR. Cytogenetics of lymphomas: a brief review of its theoretical and practical significance. Cancer Genet Cytogenet. 1997 Mar;94(1):20-6

Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000 Dec 1;96(12):3681-95

Morris SW, Xue L, Ma Z, Kinney MC. Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non-Hodgkin's lymphoma. Br J Haematol. 2001 May;113(2):275-95

This article should be referenced as such:

Huret JL. t(2;5)(p23;q35). Atlas Genet Cytogenet Oncol Haematol. 2001; 5(4):289-290.